Open Label Phase 1 Dose Finding Study of TRC105 in Patients With Solid Cancer

Inclusion Criteria:

* The patient has given informed consent.
* The patient is willing and able to abide by the protocol.
* The patient has cancer and curative therapy is unavailable.
* The patient is at least 18 years old.
* The patient has adequate ability to perform activities of daily living.
* Significant toxicities from prior therapy must have recovered.
* The patient has adequate organ function as assessed by laboratory test.

Exclusion Criteria:

* The patient weighs more than 264 lbs.
* The patient has a known allergy to gentamicin
* The patient has had prior treatment with high-dose chemotherapy requiring stem cell rescue
* The patient is currently on treatment on another therapeutic clinical trial or has received an investigational agent within 4 weeks prior to first dose with study drug
* The patient has had prior surgery (including open biopsy), radiation therapy or systemic therapy within 4 weeks of starting the study treatment
* The patient has hypertension \> 160/90
* The patient has a history of CNS cancer
* The patient has an unstable medical condition including, but not limited to, cardiac disease, history of stroke, active hepatitis, or significant pericardial, pleural or peritoneal effusion
* The patient received recent thrombolytic or anticoagulant therapy
* The patient has lung cancer with central chest lesions
* The patient has had hemorrhage or unhealed wounds within 30 days of dosing
* The patient has used systemic corticosteroids within 3 months of dosing
* The patient has known HIV/AIDS
* The patient has a history of hypersensitivity reaction to human or mouse antibody products
* The patient is pregnant or breastfeeding.
* The patient has a history of peptic ulcer disease or gastritis within 6 months of dosing, unless complete resolution has been documented by esophagogastroduodenoscopy (EGD) within 30 days of dosing